The efficacy and safety of immunosuppressants targeting the PD-1/PD-L1 pathway have been confirmed in large clinical trials of the local late maintenance therapy, late second-line therapy, and late first-line therapy of NSCLC [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.